文献速递肝病

肝硬化进一步失代偿:支持Baveno VII声明的大型多中心队列研究结果

Further decompensation in cirrhosis: Results of a large multicenter cohort study supporting Baveno VII statements.
PubMed 文献 · Hepatology · 2023-11-02

这项多中心队列研究纳入2028例肝硬化患者,评估进一步失代偿(第二次失代偿事件或并发症)的发生率及其对死亡的影响。平均随访43个月,1192例发生进一步失代偿,649例死亡,5年累积发生率分别为52%和35%。校正已知预后指标后,进一步失代偿后死亡的HR为1.46(95%CI:1.23-1.71,P<0.001),作者认为应将其视为失代偿期肝硬化更晚期阶段。

要点

  • 进一步失代偿5年累积发生率为52%,是最常见的腹水/腹水并发症。
  • 校正已知预后指标后,进一步失代偿后死亡HR为1.46(95%CI:1.23-1.71,P<0.001)。
  • 进一步失代偿后死亡和肝移植的累积发生率分别为55%和9.7%。

核心结论

  • 肝硬化中进一步失代偿发生于约60%的患者,显著增加死亡率,应被视为失代偿期肝硬化更晚期阶段。

研究设计与样本

  • 多中心队列研究,纳入2028例肝硬化患者,采用竞争风险分析评估进一步失代偿的累积发生率。
  • 构建4状态模型:首次失代偿、进一步失代偿、肝移植和死亡;采用病因特异性Cox模型评估进一步失代偿对死亡率的校正效应。
  • 对1999年前后纳入的患者进行敏感性分析。

主要发现

  • 平均随访43个月,1192例发生进一步失代偿,649例死亡;对应5年累积发生率分别为52%和35%。
  • 进一步失代偿后死亡和肝移植的累积发生率分别为55%和9.7%。
  • 最常见的进一步失代偿事件是腹水/腹水并发症。
  • 5年状态占用概率:首次失代偿存活24%,进一步失代偿存活21%,肝移植后存活7%,首次失代偿后无进一步失代偿死亡16%,进一步失代偿后死亡31%,肝移植后死亡<1%。
  • 校正已知预后指标后,进一步失代偿后死亡的HR为1.46(95%CI:1.23-1.71,P<0.001);该影响在1999年前后纳入的患者中均得到确认。

关键数值与推荐

  • 进一步失代偿定义为发生第二个事件或失代偿事件的并发症。
  • 进一步失代偿后死亡的校正HR为1.46(95%CI:1.23-1.71,P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The prognostic weight of further decompensation in cirrhosis is still unclear. We investigated the incidence of further decompensation and its effect on mortality in patients with cirrhosis. APPROACH AND RESULTS: Multicenter cohort study. The cumulative incidence of further decompensation (development of a second event or complication of a decompensating event) was assessed using competing risks analysis in 2028 patients. A 4-state model was built: first decompensation, further decompensation, liver transplant, and death. A cause-specific Cox model was used to assess the adjusted effect of further decompensation on mortality. Sensitivity analyses were performed for patients included before or after 1999. In a mean follow-up of 43 months, 1192 patients developed further decompensation and 649 died. Corresponding 5-year cumulative incidences were 52% and 35%, respectively. The cumulative incidences of death and liver transplant after further decompensation were 55% and 9.7%, respectively. The most common further decompensating event was ascites/complications of ascites. Five-year probabilities of state occupation were 24% alive with first decompensation, 21% alive with further decompensation, 7% alive with a liver transplant, 16% dead after first decompensation without further decompensation, 31% dead after further decompensation, and <1% dead after liver transplant. The HR for death after further decompensation, adjusted for known prognostic indicators, was 1.46 (95% CI: 1.23-1.71) ( p <0.001). The significant impact of further decompensation on survival was confirmed in patients included before or after 1999. CONCLUSIONS: In cirrhosis, further decompensation occurs in ~60% of patients, significantly increases mortality, and should be considered a more advanced stage of decompensated cirrhosis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. D'Amico G, Zipprich A, Villanueva C, et al. Further decompensation in cirrhosis: Results of a large multicenter cohort study supporting Baveno VII statements. Hepatology. 2023. PMID: 37916970. doi:10.1097/HEP.0000000000000652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。